Overview of Алпростадил

What is Алпростадил? Defining a Potent Vasodilator

Property	Description
Active ingredient	Alprostadil (Prostaglandin E1 Analog)
Forms	Powder for solution, Intraurethral pellet, Topical cream/gel
Pharmacological class	Prostaglandin Analog, Potent Vasodilator
Common general purpose	Localized blood flow enhancement
Origin	Synthetic (PGE1 Analog)

Алпростадил (Alprostadil) is a synthetic drug classified as a Prostaglandin Analog and a potent vasodilator. It is chemically identical to the naturally occurring substance Prostaglandin E1 (PGE1) found in the human body. This prescription-only compound provides a reliable, manufactured source of PGE1 and is clinically recognized for its ability to directly influence smooth muscle activity.

Composition, Origin, and Specialized Forms

The medication is a single-component drug whose sole active ingredient is Alprostadil. A distinctive feature of Alprostadil is the necessity for highly specialized delivery systems due to its rapid metabolism in the bloodstream, requiring its effects to be concentrated locally. For this reason, it is formulated into distinct pharmaceutical preparations, including a powder for solution for injection or infusion, an intraurethral pellet (suppository), and specific topical cream/gel preparations. These diverse, non-oral forms dictate precise administration routes—such as Intracavernosal, Intra-arterial, Intravenous, Intraurethral, and Topical—ensuring therapeutic efficacy by minimizing systemic exposure.

General Action and Primary Therapeutic Purpose

Alprostadil’s primary physiological action is to directly induce the relaxation of smooth muscle tissue, resulting in the pronounced widening of blood vessels (vasodilation). This powerful local effect is the reason for its clinical utilization in settings requiring acute and focused circulatory improvement, such as temporarily maintaining vascular patency in specific patient populations. This focused increase in blood flow serves as the fundamental general purpose guiding its use in specialized medical contexts.

What side effects are possible with Алпростадил?

The possible side effects and safety characteristics of Alprostadil are derived from official regulatory documents, classifying reactions based on frequency and organ system affected.

Official Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized, with Penile pain (for injection) and Urethral pain (for intraurethral pellet) consistently classified as Very Common (1/10). Other frequently documented effects include injection site hematoma/ecchymosis, headache, and dizziness, which are listed as Common (1/100 to < 1/10) in official regulatory summaries.

System Organ Class	Common Adverse Reaction Examples	Very Common Adverse Reactions
Genitourinary System	Prolonged erection (4–6 hours), Penile fibrosis	Penile pain, Urethral burning
Cardiovascular System	Hypotension	Flushing (Vasodilatation)
Nervous System	Headache, Dizziness	—

Serious Adverse Reactions and Special Populations

Regulatory documentation highlights specific low-frequency, yet serious, adverse events. Priapism (an erection lasting over six hours) is documented as an Uncommon (1/1000 to < 1/100) but clinically significant risk that requires prompt intervention. In post-marketing reports, serious events such as Myocardial ischaemia and Cerebrovascular accident are noted, though the frequency is classified as Not Known.

Specific safety considerations are defined for certain populations and conditions:

Neonates: For infants receiving continuous infusion, the risk of Apnea is classified as Very Common, particularly in those with a lower body weight. The development of Gastric outlet obstruction is also documented as a risk related to the duration of therapy and cumulative dose.
Safety Constraints: The official labeling stipulates that individuals with penile anatomical deformations (e.g., severe angulation, cavernosal fibrosis) are associated with safety restrictions due to the risk of tissue damage. Patients with predisposing conditions such as sickle cell anemia or multiple myeloma also have specific warnings related to the risk of priapism.

The overall safety profile is structured to account for both the highly frequent, localized effects stemming from the drug's potent vasodilatory action and the necessary surveillance for low-frequency, high-severity systemic and genitourinary complications.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose manifestations and required emergency actions for Alprostadil is derived exclusively from authoritative government regulatory documents.

Documented Overdose Presentations

Classification	Clinical Manifestations (Regulatory Descriptions)
Systemic Overexposure	Severe hypotension, tachycardia, and widespread cutaneous flushing.
Localized Overdose	Prolonged erection (4–6 hours) and priapism (over 6 hours).
Neonatal Overdose	Apnea, bradycardia, and pyrexia, particularly in neonates under 2 kg.

Regulatory Mandates for Emergency Action

Overdose from Alprostadil is primarily managed through symptomatic and supportive treatment, as no specific antidote is known. The official guidance strongly mandates urgent medical intervention in specific scenarios:

Priapism: An erection that persists for longer than 4 hours requires the patient to seek immediate medical assistance. Regulatory documents emphasize that treatment for priapism must not be delayed more than six hours, due to the documented risk of permanent tissue damage.
Systemic Symptoms: Any signs of severe systemic overexposure, such as profound hypotension or cardiovascular instability, require the patient to contact emergency services immediately.
Monitoring: Continuous cardiovascular monitoring and hospital observation are required until symptoms are fully resolved and vital signs have stabilized.

Therapeutic Uses of Алпростадил

What Алпростадил Treats: Main Uses and Benefits

This medication is generally used in two main therapeutic contexts.

The primary use is managing symptoms of erectile dysfunction (ED), which involves symptoms of functional strain. It is also applied for the short-term, acute stabilization of newborns with specific congenital heart defects. This medication is applied across different condition categories, including conditions presenting with episodic, functional stress, and in critical situations requiring temporary physiological support.

For erectile dysfunction, this medication helps address symptom clusters that create noticeable physiological strain, particularly when other symptomatic management approaches have not been suitable. The therapeutic benefit supports patients during episodes of heightened discomfort related to functional challenges.

“This medication is considered relevant as a therapeutic option in contexts marked by increased discomfort or tension related to functional challenges.”

Quick Support Focus This medication is often used when symptoms intensify and supportive relief is needed, providing an option that contributes to improved comfort during periods of heightened symptoms.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This section outlines the officially documented population eligibility and exclusion rules for Alprostadil, as defined by government regulatory agencies (e.g., FDA, EMA).

Eligibility Scope

Classification	Eligible Populations
Indicated Use	Adult Males (for Erectile Dysfunction) and Neonates (for temporary maintenance of Ductus Arteriosus patency).
Not Indicated	Women and Children (for Erectile Dysfunction formulations).

Absolute Contraindications

Alprostadil is formally prohibited for use in men with the following conditions, as they significantly increase the risk of severe complications, such as priapism, or interfere with localized administration:

Predisposition to Priapism: Patients with blood disorders such as sickle cell anemia/trait, multiple myeloma, or leukemia.
Penile Anatomical Defects: Men with penile implants or fibrotic conditions including Peyronie's disease, angulation, or cavernosal fibrosis.
Hypersensitivity: Known allergy to alprostadil or any excipients.
Cardiovascular Status: Men for whom sexual activity is inadvisable due to an unstable cardiovascular or cerebrovascular condition.

Conditions for Restricted or Conditional Use

Use is subject to caution and medical monitoring in specific populations due to the potential for altered effects or increased risk:

Organ Function: Patients with renal or hepatic impairment, as pharmacokinetics have not been fully established, potentially requiring special consideration in older adults.
Anticoagulant Use: Patients taking blood thinners (e.g., warfarin) may have an increased tendency for injection site bleeding.
Neonatal Risk: Neonates, particularly those weighing less than 2 kilograms, require continuous respiratory monitoring due to an increased risk of apnea.
Pregnancy/Lactation: The male patient must use a condom barrier during sexual intercourse with a pregnant or child-bearing partner.

What should I know about interactions with other medicines?

Алпростадил Interactions with other medicines and products

Official regulatory information for Алпростадил focuses predominantly on interactions related to its primary vasodilatory and anti-platelet effects, which are pharmacodynamic in nature.

Documented Interaction Categories

Classification	Interacting Agents and Official Description
Prohibited Combinations	The co-administration of other vasoactive agents for erectile dysfunction, including PDE5 Inhibitors (e.g., Sildenafil) and other intracavernosal drugs, is not recommended or prohibited. This restriction is documented due to the increased risk of inducing a prolonged erection or priapism [Source 1.1, 2.2].
Pharmacodynamic Risks	Anticoagulants (e.g., Warfarin, Heparin) and Platelet Aggregation Inhibitors may cause an increased propensity for bleeding at the administration site due to Alprostadil's documented inhibitory effect on platelet function [Source 1.1, 2.2].
	Antihypertensives and Systemic Vasodilative Agents may have their effects enhanced, leading to a potentially increased risk of systemic hypotension [Source 2.2].
Exposure/Metabolism	The potential for pharmacokinetic drug-drug interactions has not been formally studied, and such interactions are considered unlikely given the medicine’s rapid, local metabolism [Source 1.5].
Substance & Population Notes	Alcohol (Ethanol) may decrease the effectiveness of the medication [Source 4.3]. The risk of hypotension is noted as potentially more common in elderly patients when co-administered with vasodilators [Source 2.7]. Benzyl alcohol (an excipient) carries a risk of accumulation and toxicity in patients with severe liver or kidney impairment [Source 3.4].

These interaction statements define the product's regulatory profile, emphasizing constraints against co-administration with other potent vasodilators to manage additive safety risks. The official documentation clearly states that the primary concerns are related to pharmacodynamic amplification (bleeding and hypotension) rather than modifications in systemic drug exposure.

Mechanism of Action

How Alprostadil Works

Alprostadil, a synthetic analog of prostaglandin E1 (PGE1), initiates its pharmacodynamic action through direct engagement with specific G protein-coupled prostaglandin receptors on smooth muscle cell membranes.

Receptor Agonism and Pathway Initiation

Alprostadil functions as an agonist, binding to receptors, primarily the EP2 receptor subtype. This binding event triggers the activation of the enzyme adenylate cyclase located within the cell membrane. This represents the immediate intracellular effect, leading to the synthesis of a key second messenger.

Cyclic AMP Cascade and Intracellular Calcium

The resulting stimulation of adenylate cyclase significantly increases the intracellular concentration of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels activate downstream protein kinases, initiating a cascade of phosphorylation events that ultimately lead to the sequestration or decreased influx of calcium ion (Ca^2+) within the muscle cell cytoplasm.

Smooth Muscle Relaxation

This reduction in cytoplasmic Ca^2+ concentration is the final molecular event that causes the relaxation of both vascular and non-vascular smooth muscle. The direct physiological consequence of this relaxation is localized vasodilation.

Dosage and Administration Information

Alprostadil is administered through specialized, non-oral routes, including intracavernosal injection, intraurethral pellet insertion, topical application, and continuous intravenous (IV) infusion. The specific route is determined by the indication and the pharmaceutical form.

Official Administration Guidelines

Category	Official Instruction
Route & Dosing Schedule	Adult ED starting doses range from 1.25 mcg (injection) up to 250 mcg (intraurethral) and are titrated under supervision to the lowest effective maintenance dose.
Preparation	Powder forms require mandatory reconstitution with a specific diluent prior to use; solutions and devices are for single use only.
Frequency Pattern	Use for ED is limited to no more than three times per week with a mandatory minimum interval of 24 hours between administrations.
Age-Group Rules	Pediatric (Neonates): IV infusion for PDA begins at 0.05 to 0.1 mcg/kg/min and must be titrated downward to the lowest effective rate upon achieving a response.

Resulting Procedural Structure

The medicine's use is structured by several procedural steps:

The initial administration and dose determination for self-administered forms must occur under direct medical supervision in a healthcare setting.
The established maintenance dose must not produce an effect that exceeds one hour in duration, defining the required end-point of the titration process.
Intracavernosal administration requires sites to be alternated, and continuous IV infusion is restricted to clinical settings capable of providing pediatric intensive care.

Recent Clinical Evidence

Research evidence / Overview of studies for Алпростадил

Research in Conditions Marked by Functional Limitations (Erectile Dysfunction)

Studies have explored the use of Алпростадил in men dealing with conditions marked by functional limitations, specifically focusing on the outcomes reflecting daily functioning or activity level. Research examined different methods of administration to understand how symptoms evolved in the observed populations. These studies often applied patient-reported experiences to assess the impact of the treatment on perceived discomfort and overall function.

Local Administration in Men

Local administration, via injection or intraurethral pellet, was evaluated in research exploring short-term symptom changes and episodic symptom patterns. Research examined measurements of outcomes reflecting daily functioning or activity level, such as penetration and completion of intercourse, during defined time intervals.

Findings describe the measurements collected from men using specific patient-reported outcomes describing perceived discomfort. Research examined measurements of outcomes reflecting daily functioning or activity level, such as penetration and completion of intercourse, during defined time intervals.

However, when reviewing the evidence, several limitations are noted. While outcomes monitored physiological strain were generally recorded, the follow-up durations were limited in many initial studies, meaning long-term effects are not fully established. Furthermore, some research suggests that the response to local administration remained stable, and data related to the restoration of natural erectile function were not the primary focus during the extension phase between 12 and 24 months of continued use. Therefore, findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Other Research Scenarios in Men

Studies also monitored the use of a topical cream formulation of Алпростадил. This research examined temporary physiological imbalance, specifically focusing on the local changes measured in the penis. Findings describe patterns observed in trials comparing the cream to a placebo, where measurements of outcomes reflecting daily functioning or activity level were noted over the short term (typically up to 12 weeks).

Despite these findings, comparative evidence is lacking. The research exploring short-term symptom changes with the topical cream lacks comparative evidence involving other available treatments. Furthermore, the available data are still emerging regarding very long-term use; there is limited information for outcomes beyond approximately nine months of continuous use, meaning certainty remains low regarding effects over multiple years.

Other Areas of Research: Neonatal and Vascular Conditions

Алпростадил was evaluated in critical, short-term research scenarios involving neonates with certain congenital heart defects. This approach was studied for its role in maintaining a temporary physiological balance until definitive surgical treatment could be performed.

Research describes findings related to temporary physiological balance during the acute stabilization period in neonates. Studies in certain specific cases are limited, and results apply only to the populations studied, with data for certain groups remaining insufficient. The research focuses exclusively on the acute stabilization period (days), and data regarding long-term developmental outcomes remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Алпростадил (FAQ)

Q: Why do some people consider Alprostadil a hormone?

A: Alprostadil is chemically synthesized to be an analog of Prostaglandin E1 (PGE1), which is a lipid compound naturally found in the body.

Official drug classification lists it as a Prostaglandin Analog and a potent vasodilator, not a hormone.

Q: How quickly does Alprostadil start working after use?

A: According to the official product information for the intracavernosal injection, an effect usually begins within 5 to 20 minutes after administration.

The total duration of the effect is dependent on the specific dose received during the medical titration process.

Q: Are there long-term risks associated with repeated use of Alprostadil?

A: Official safety data indicates that a long-term risk of repeated use includes the potential development of penile fibrosis (the formation of scar tissue in the penis).

This potential risk was observed in clinical studies and is noted in regulatory summaries.

Q: How is Alprostadil different from PDE-5 inhibitors?

A: Alprostadil has a different mechanism of action than PDE-5 inhibitors (such as sildenafil).

Official pharmacological descriptions state that Alprostadil works by activating the enzyme adenylate cyclase, which increases the level of cyclic AMP (cAMP) and leads to smooth muscle relaxation.

Q: Does Alprostadil affect the ability to conceive?

A: Official warnings for some forms state that the medication should not be used while attempting to achieve a pregnancy.

Regulatory documents note that if a male patient is sexually active with a pregnant partner, the use of barrier contraception is necessary. Direct data on the effect on sperm fertility are generally not provided in the primary regulatory documentation.

Q: Are there age restrictions for using Alprostadil?

A: Official regulatory documents do not specify an upper age limit for adult use of Alprostadil.

However, a potential risk is noted for elderly patients, as they may have an increased risk of systemic hypotension (low blood pressure) when the drug is co-administered with other vasodilators.

Q: Does smoking or alcohol consumption affect the action of Alprostadil?

A: Official patient information indicates that the use of alcohol may reduce the effectiveness of Alprostadil.

Official product information emphasizes the importance of reviewing both alcohol and tobacco use with a healthcare provider, as both may affect the medication.

Q: Is there research data on the safety of Alprostadil with long-term use?

A: Official research summaries note that in some clinical studies, the duration of follow-up was limited, typically up to 18 months.

Therefore, complete safety data spanning multiple years of continuous use may be restricted, though risks like fibrosis were tracked in these studies.

Q: What should be done if a side effect does not subside within the expected time?

A: Regulatory warnings state that an erection persisting for longer than 4 hours constitutes a medical emergency and requires prompt clinical intervention.

This symptom is known as priapism.

Q: In which cases is Alprostadil considered ineffective?

A: Official regulatory documents state that the medication is contraindicated (prohibited) for men with certain penile anatomical defects, such as Peyronie's disease or cavernosal fibrosis.

In such cases, the drug may be ineffective and could pose a risk of tissue damage.

Q: What is known about the safety of Alprostadil for the liver and kidneys?

A: Official product information notes that use is subject to special consideration for patients who have pre-existing renal (kidney) or hepatic (liver) impairment.

Regulatory documents also highlight a risk associated with the excipient benzyl alcohol for patients with severe organ dysfunction.

Q: Is it true that Alprostadil can be used for Raynaud's disease?

A: Alprostadil is not officially indicated for the treatment of Raynaud's disease.

Its regulatory approvals are strictly defined for erectile dysfunction in adult males and for temporarily maintaining the patency of the ductus arteriosus in neonates.

Q: Can people with diabetes safely use Alprostadil?

A: According to official documents, diabetes itself is not listed as an absolute contraindication to the drug's use.

The safety for a patient with diabetes depends on their overall cardiovascular health and the absence of other specific contraindications, such as blood disorders.

Q: Is Alprostadil considered an addictive substance?

A: Regulatory documents do not mention any potential for abuse, physical dependence, or addiction associated with Alprostadil.

Q: Why might doctors prefer Alprostadil over other treatments?

A: Official clinical trial summaries suggest Alprostadil may be an option for patients who have not responded adequately to oral PDE-5 inhibitors (such as sildenafil) or who have specific contraindications that prevent them from using those treatments.

Q: Can some foods affect the metabolism of Alprostadil?

A: Regulatory patient information for certain forms of Alprostadil (such as the topical cream) states that the product does not interact with food intake.

The rapid, localized metabolism of the drug means systemic food-drug interactions are considered unlikely.

Q: Are there alternative names or brands for Alprostadil?

A: Yes, the active ingredient Alprostadil is available under several common brand names.

These include Caverject, Edex, and Muse, among others.

Q: Is there data on Alprostadil overdose?

A: Data on overdose indicate that the most significant symptom is a prolonged erection, or priapism, lasting longer than 6 hours.

Systemic effects of overdose may also include dizziness, fainting, or blurred vision.

How should Алпростадил be stored and disposed of?

Official Storage and Disposal Instructions

The required storage conditions for alprostadil formulations are defined by regulatory labeling and depend on the product form. The powder for solution (injection) is typically stored at controlled room temperature, generally not exceeding 25 C (77 F), while the intraurethral pellet requires mandatory storage under refrigeration. Both forms are strictly labeled with the requirement to not freeze.

Once the powder for solution is reconstituted, it has a limited stability period and must be used immediately or within 24 hours, depending on the specific formulation. All alprostadil products must be stored out of the sight and reach of children.

For disposal, the product is single-use. Used needles and syringes associated with the injection must be placed immediately into an FDA-cleared sharps disposal container. They must not be thrown into household trash or flushed.

Алпростадил